PREVIOUS QUESTION:

 

NEXT QUESTION:

 

How many people in the U.S. have migraines?

ANSWER

As many as 18% of women and 6% of men in the U.S. have migraine. Yet despite how common these painful, throbbing headaches are, treatment often remains a challenge.

NeuroSciences : “New advances in prevention of migraine: Review of current practice and recent advances.”

Functional Neurology : “Migraine as a complex disease: heterogeneity, comorbidity and genotype-phenotype interactions.”

National Headache Foundation: “Facts about Triptans,” “Migraine.”

Expert Reviews of Clinical Pharmacology : “The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache.”

Mayo Clinic: “Migraine: Treatment.”

The Lancet Neurology : “Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study,” “Headache research in 2015: progress in migraine treatment.”

Neurology : “TEV-48125 for the preventive treatment of chronic migraine.”

Hormone Health Network/Endocrine Society: “What Do Prostaglandins Do?”

Current Opinion in Neurology : “Prostaglandins in migraine: update.”

The DANA Foundation: “Theory Behind Migraine Emerges.”

The Migraine Trust: “Transcranial magnetic stimulation (TMS).”

American Migraine Foundation: “Behavioral Treatment of Headache and Migraine Patients -- Making Referrals,” “Biofeedback and Relaxation Training for Headaches.”

Medscape: “Phase 3 STRIVE and ARISE Trials Show Efficacy, Safety for Erenumab in Migraine Prevention,” “Positive Phase 3 Results for Fremanezumab in Migraine.”

Reviewed by Melinda Ratini on February 18, 2019

NeuroSciences : “New advances in prevention of migraine: Review of current practice and recent advances.”

Functional Neurology : “Migraine as a complex disease: heterogeneity, comorbidity and genotype-phenotype interactions.”

National Headache Foundation: “Facts about Triptans,” “Migraine.”

Expert Reviews of Clinical Pharmacology : “The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache.”

Mayo Clinic: “Migraine: Treatment.”

The Lancet Neurology : “Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study,” “Headache research in 2015: progress in migraine treatment.”

Neurology : “TEV-48125 for the preventive treatment of chronic migraine.”

Hormone Health Network/Endocrine Society: “What Do Prostaglandins Do?”

Current Opinion in Neurology : “Prostaglandins in migraine: update.”

The DANA Foundation: “Theory Behind Migraine Emerges.”

The Migraine Trust: “Transcranial magnetic stimulation (TMS).”

American Migraine Foundation: “Behavioral Treatment of Headache and Migraine Patients -- Making Referrals,” “Biofeedback and Relaxation Training for Headaches.”

Medscape: “Phase 3 STRIVE and ARISE Trials Show Efficacy, Safety for Erenumab in Migraine Prevention,” “Positive Phase 3 Results for Fremanezumab in Migraine.”

Reviewed by Melinda Ratini on February 18, 2019

NEXT QUESTION:

How do triggers of migraines vary?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.